Author  
Place of duty  
Title   1 선 항암화학요법에 반응이 없거나 재발한 위암환자에서 Etoposide , Doxorubicin , Cisplatin ( EAP ) 복합화학요법의 효과 ( Combination Chemotherapy with Etoposide , Doxorubicin , Cisplatin ( KAP ) for Recurred or Metastatic Gastric Cancer Refractory to Prior Chemotherapy )
Publicationinfo   2000 Jan; 032(03): 524-531.
Key_word   Stomach neoplasm , Etoposide , Doxorubicin , Cisplatin , Chemotherapy
Full-Text  
Abstract   Purpose: We performed this study to evaluate the efficacy and the safety of EAP regimen as a second line therapy for the recurred or metastatic gastric cancer unresponsive to 5-fluorouracil based chemotherapy. Materials and Methods: Recurred or metastatic gastric cancer patients unresponsive to 5-fluorouracil based regimen were entered into this trial. They were treated by EAP chemotherpy which consisted of etoposide 40 mg/m, doxorubicin 15 mg/m and cisplatin 25 mg/m IV during 3 days each every 3 weeks. Results: From December 1994 to March 1998, Eighteen patients were enrolled in this protocol, Fourteen patients were evaluable for response. The overall response rate was 28.6% (95% CI: 11.7-56.7%). The median response duration was 21 weeks. The median survival for all enrolled patients was 28 weeks. The major toxicity was myelosuppression. Among total of 69 cycle chemotherapy, WHO grade 3 or 4 granulocytopenia and thrombocytopenia were observed in 71.0% and 27.5%, respectively, Conclusion: Second line therapy with EAP regimen was active for gastric cancer. Chemotherapy induced toxicities were moderate to severe.
저 자   이승철(Seung Cheol Lee),박연희(Yeon Hee Park),조남국(Nam Kuk Cho),최대식(Tae Sik Choi),유영진(Young Jin Yuh),김성록(Sung Rok Kim)